Brucella Cyclic Beta Glucans as TLR4 Agonists for Vaccine Adjuvants

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunoadjuvants used in vaccines can elicit adverse side effects and are limited in their effectiveness, necessitating the development of new compounds that can enhance immune responses without triggering endotoxic side effects.

Innovation Solution

Brucella cyclic beta glucans (CβG) are identified as a novel class of immunoadjuvants that act as TLR4 agonists, inducing dendritic cell maturation, pro-inflammatory cytokine secretion, and T cell activation, thereby enhancing immune responses without significant systemic endotoxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional immunoadjuvants (mineral oils, bacterial extracts, aluminum hydroxide) are used to enhance immune responses, then vaccine efficacy is improved, but adverse side effects including endotoxic effects are triggered

Engineering Contradiction:

Improvevaccine efficacyVSAvoidadverse side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and isolates the beneficial immunoadjuvant properties from bacterial components while removing the harmful endotoxic LPS portion. Specifically, cyclic beta-glucans are purified from Brucella abortus cells, separating the immunostimulatory glucan component from the endotoxic lipopolysaccharide, thereby maintaining vaccine efficacy while eliminating adverse side effects

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts the harmful endotoxic effects of bacterial components into a beneficial outcome by using cyclic beta-glucans that selectively activate immune receptors (Dectin-1, TLRs) without triggering LPS-mediated endotoxicity. The glucans harness the body's natural immune recognition pathways to enhance vaccine responses while avoiding the harmful inflammatory responses associated with conventional adjuvants

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Productivity

If immunoadjuvants are used to stimulate immune responses, then immune activation is enhanced, but the number of approved adjuvants remains limited due to safety concerns

Engineering Contradiction:

Improveimmune response enhancementVSAvoidadjuvant availability

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent demonstrates that cyclic beta-glucans possess multiple immunomodulatory functions: they activate dendritic cells via Dectin-1, stimulate TLR pathways, enhance both humoral and cell-mediated immunity, and work across different vaccine types. This multi-functionality makes them a versatile adjuvant platform that can be applied to various vaccines beyond what is currently approved

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent modifies the chemical structure parameters of glucans by creating cyclic beta-1,2-linked structures with specific degree of polymerization (DP 6-15). These structural parameter changes optimize the immunoadjuvant properties while maintaining safety, resulting in a new class of adjuvants with enhanced efficacy and broader applicability

Inventive Principle:

Principle #35Parameter changes

3Reliability

If linear beta-glucans are used as immunoadjuvants, then immune responses are stimulated, but cyclic beta-glucans provide superior adjuvant activity with reduced side effects

Engineering Contradiction:

Improveimmune responseVSAvoidendotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent exploits the structural asymmetry between linear and cyclic beta-glucan configurations. The cyclic structure with beta-1,2 linkages creates a specific three-dimensional conformation that selectively binds to immune receptors (Dectin-1, TLRs) with higher affinity and specificity than linear glucans, enhancing immune activation while avoiding off-target effects and endotoxicity

Inventive Principle:

Principle #4Asymmetry

Solution Approach 2:

The patent creates a composite immunoadjuvant system where cyclic beta-glucans work synergistically with antigens and other vaccine components. The glucans form a protective complex with the antigen that enhances uptake by antigen-presenting cells while the cyclic structure provides structural stability and controlled release properties

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Brucella CβG effectively activate mouse and human dendritic cells, promoting immune responses and inducing T cell proliferation, offering a new class of immunoadjuvants that can enhance vaccine efficacy without adverse side effects.

Implementation Method 1

Methodology Applied

Scientific EffectToll-like receptor 4 agonism:

Implementation Method 2

DCs recognize microbial stimuli, also called pathogen associated molecular patterns (PAMPs), by highly conserved receptors pattern-recognition receptors (PRRs). When these receptors are triggered, downstream signalling cascades are activated for induction of inflammatory responses.

Methodology Applied

Scientific EffectReceptor-ligand binding:

Data Source

PatentUS9061066B2Immunoadjuvant compounds and uses thereof

Publication Date: 2015.06.23 INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)

AI summary

Cyclic beta glucan compounds function as an immunoadjuvant when administered prior to, concommitantly with, or subsequent to the administration of one or more antigens to a subject. These adjuvant compounds may be effectively used as dendritic cell activating molecules.